WallStreetZenWallStreetZen

NASDAQ: IMDX
Insight Molecular Diagnostics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Insight Molecular Diagnostics revenue was $3.84M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $2.1M, up 43.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IMDX annual revenue was $1.9M, with 25.1% growth year-over-year.

IMDX past revenue growth

How has IMDX's revenue growth performed historically?

Company
178.08%
Industry
4.62%
Market
35.64%
IMDX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IMDX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IMDX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IMDX revenue history

Current Revenue
$3.8M
Current Earnings
-$58.3M
Current Profit Margin
-1,516.1%

Be the first to know when IMDX announces revenue.

IMDX Revenue History By Year

IMDX Yearly RevenueIMDX RevenueIMDX ChangeIMDX Revenue Growth
2024-12-31$1.88M$378.00k+25.15%
2023-12-31$1.50M$545.00k+56.89%
2022-12-31$958.00k-$1.24M-56.41%
2021-12-31$2.20M$982.00k+80.76%
2020-12-31$1.22MN/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A

1 of 1

Insight Molecular Diagnostics Revenue FAQ

What was IMDX's revenue last quarter?

On Invalid Date, Insight Molecular Diagnostics (NASDAQ: IMDX) reported Q1 2025 revenue of $2.14 million up 1,114.77% year over year. In the same quarter last year, Insight Molecular Diagnostics's revenue was $176.00 thousand.

What was Insight Molecular Diagnostics's revenue in 2024?

Insight Molecular Diagnostics's annual revenue for the twelve months ending Dec 31, 2024 was $1.88 million, a 25.15% increase year over year.

How much does Insight Molecular Diagnostics make in a day?

Based on Insight Molecular Diagnostics annual revenue for the past five years, IMDX makes an average of $4,249.86 per day.

What was Insight Molecular Diagnostics's annual revenue growth in the past year?

As of Q2 2025, Insight Molecular Diagnostics's revenue has grown 178.08% year over year. This is 173.45 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 4.62%. Insight Molecular Diagnostics's revenue in the past year totaled $3.84 million.

How much does Insight Molecular Diagnostics make in a year?

Insight Molecular Diagnostics's revenue by year for the past five years is:
  • Insight Molecular Diagnostics's revenue for the twelve months ending Dec 31, 2024 was $1.88 million, a 25.15% increase year over year.
  • Insight Molecular Diagnostics's annual revenue for Dec 31, 2023 was $1.50 million, a 56.89% increase from 2022.
  • Insight Molecular Diagnostics's annual revenue for 2022 was $958.00 thousand, a 56.41% decrease from 2021.
  • Insight Molecular Diagnostics's annual revenue for 2021 was $2.20 million, a 80.76% increase from 2020.
  • Insight Molecular Diagnostics's annual revenue for 2020 was $1.22 million, a Infinity% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.